Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option
Failure of integrase inhibitor-based regimens may be due to a completely novel form of resistance
Weight loss after treatment switch more likely for those with higher body mass
White blood cell changes on islatravir do not lead to a higher risk of infections
HIV infections acquired while on injectable PrEP may take a very long time to be spotted
Promising new PrEP method undergoes first safety study for anal sex
Combinations containing TAF and cobicistat linked to physical depression symptoms in women with HIV
San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Switching to injectable cabotegravir and rilpivirine rarely affects body weight
